The ‘nocebo’ effect: how informed consent can cause unnecessary harm in clinical trials

clinical trials effect nocebo unnecesary harm

The ‘nocebo’ effect: how informed consent can cause unnecessary harm in clinical trials

Nocebo effect

University of Oxford
 
Research published today in the Journal of Medical Ethics found that the way informed consent is currently taken causes unnecessary ‘nocebo’ harms.
 
The requirement of informed consent means that it is an ethical requirement to warn patients about risks of taking part in clinical trials. But recent research shows that the way in which patients are told about these risks can actually cause harm.
 
Dr Jeremy Howick, Director of the Oxford Empathy Programme, Faculty of Philosophy, and study author, says: ‘Sometimes when we warn patients about negative side effects in a scary way it actually causes the negative side effect (a ‘nocebo effect’).’
 
A mega-study cited in the paper found that half of the 250,000 patients who took placebo pills (like sugar pills) in clinical trials reported some negative side effects (like pain or nausea but also more serious things). Current requirements for taking informed consent force ethics committees to focus on talking a lot about trial harms. This is understandable from a medico-legal perspective.
 
Researchers are concerned about ‘outlier’ cases where a patient might say that they were not sufficiently well informed about a potential harm which they experienced. But talking about harms in the wrong way can cause its own harm. This study shows that ethics committees need to take these ‘nocebo’ harms seriously.
 
There are emerging ways to share risks with patients without causing unnecessary nocebo effects. Foremost among these is positive framing.
 
Dr Howick says: ‘You can tell a patient, “10% of the people who take this drug have a negative side-effect”, or you can say, “90% of the people don’t have any negative side-effects”. In both cases the information is the same, but the first way leads to more reported side-effects.
 
‘Ethics committees need to take the reality of nocebo effects into account, and balance the need to inform patients with the need to inform them the right way.’
 
ENDS
 
 
Funding
This study was not externally funded.
 
Notes to editors
For further information or comment, please contact Dr Jeremy Howick, Senior Researcher and Director of the Oxford Empathy Programme, Faculty of Philosophy, University of Oxford, Jeremy.howick@philosophy.ox.ac.uk
 
Paper reference
Howick J
Unethical informed consent caused by overlooking poorly measured nocebo effects
Journal of Medical Ethics  Published Online First: 16 February 2020. doi: 10.1136/medethics-2019-105903 
 


Publicación más antigua Publicación más reciente